List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Portable Ultrasound Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 110 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 110 pages
- Published: 13-06-2019
Market Overview
Factors that are responsible for the growth of the portable ultrasound devices market include increasing spectrum of applications of the portable ultrasound, increasing advancements in technology, and the growing prevalence of chronic diseases.
The introduction of portable ultrasound devices has a variety of applications in many emerging fields, like emergency medicine, critical care medicine, and musculoskeletal. Portable ultrasound devices are used for easy access to ultrasound when limited space is there. Currently, these devices are being used in the major areas of diseases, such as cardiology, radiology endocrinology and gynecology. Since there is a rising need for ambulatory services across developing as well as developed countries, the demand for portable ultrasound devices is increasing, which is leading to the growth of the market.
Scope of the Report
Portable ultrasound systems are small devices compared to traditional ultrasound systems. These devices are lightweight and easy to handle.
Key Market Trends
Mobile Ultrasound Device is Expected to Grow with High CAGR
The mobile ultrasound device segment of the portable ultrasound devices market is expected to experience the fastest growth rate over the forecast period.
Mobile ultrasound devices are gaining attraction in the developing regions, due to the rising demand for ambulatory care. Although developed countries, like the United States, have a well-established market for handheld ultrasound devices, there is also a rising demand for mobile ultrasound devices. Due to its efficacy in providing mobile care, the segment is expected to grow rapidly over the forecast period.
North America Dominates the Market and Expected to Follow the Same Trend Over the Forecast Period
North America currently dominates the portable ultrasound devices market and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. This can be majorly attributed to the increasing incidences of chronic disorders, rising demand for advanced ultrasound systems, and the presence of the developed healthcare infrastructure.
Competitive Landscape
The portable ultrasound devices market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising need of mobile health and the advancements in ultrasonography, few smaller players are entering the market and holding a substantial share. Some of the major players of the market are Fukuda Denshi, Hitachi Ltd, Koninklijke Philips NV, Canon Medical Systems Corporation, and Siemens Healthineers, among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Spectrum of Applications of Portable Ultrasound
4.2.2 Increasing Advancements in Technology
4.2.3 Increasing Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 High Cost of Portable Ultrasound Systems
4.3.2 Lack of Dedicated Training Programs by Companies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Device
5.1.1 Mobile Ultrasound Device
5.1.2 Handheld Ultrasound Device
5.2 By Area of Application
5.2.1 Traditional Areas
5.2.1.1 Radiology
5.2.1.2 Gynecology
5.2.1.3 Cardiology
5.2.1.4 Urology
5.2.1.5 Other Traditional Areas
5.2.2 Emerging Areas
5.2.2.1 Emergency Medicine
5.2.2.2 Anesthesiology
5.2.2.3 Critical Care Medicine
5.2.2.4 Musculoskeletal
5.2.3 By End User
5.2.3.1 Hospitals
5.2.3.2 Diagnostic Centers
5.2.3.3 Ambulatory Care Centers
5.2.3.4 Other End Users
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Fujifilm SonoSite Inc.
6.1.2 GE Healthcare
6.1.3 Hitachi Ltd
6.1.4 Shenzhen Mindray
6.1.5 Canon Medical Systems Corporation
6.1.6 Koninklijke Philips NV
6.1.7 Samsung Healthcare
6.1.8 Siemens Healthineers
6.1.9 Fukuda Denshi Co. Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type of Device
Mobile Ultrasound Device
Handheld Ultrasound Device
By Area of Application
Traditional Areas
Radiology
Gynecology
Cardiology
Urology
Other Traditional Areas
Emerging Areas
Emergency Medicine
Anesthesiology
Critical Care Medicine
Musculoskeletal
By End User
Hospitals
Diagnostic Centers
Ambulatory Care Centers
Other End Users
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Platelet Rich Plasma Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 114 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 114 pages
- Published: 07-06-2019
Market Overview
The global platelet-rich plasma market is expected to register a CAGR of approximately 14% over the forecast period. The key factors that are augmenting the growth of the market include rising incidences of sports injuries, increasing number of androgenic alopecia patients, growing use of platelet-rich plasma in various therapeutic areas, and rise in the prevalence of arthritis.
Osteoarthritis (OA) is the most common form of chronic disorder of the joints, and it has some detrimental effects on the quality of life of the patients. Progressive cartilage destruction, osteophyte formation, and subchondral sclerosis are characteristic to osteoarthritis. Platelet-rich plasma (PRP) is an autologous concentration of a high number of platelets in a small volume of plasma. PRP is prepared to centrifuge blood. In knee OA, PRP injections target to promote cartilage repair in order to relieve symptoms of osteoarthritis, hence delaying the need for joint replacement surgery.
The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.
Scope of the Report
As per the scope of the report, platelet-rich plasma (PRP) prolotherapy, like dextrose prolotherapy, is a method of injection designed to stimulate healing. Platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels, which contains at least seven growth factors.
Key Market Trends
Pure PRP Segment by Type is Expected to Hold the Largest Market Share
The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.
The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.
Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.
North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years
North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US government’s initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.
Competitive Landscape
Companies, such as Biotest AG, China Biologic Products Inc., CSL Ltd, Octapharma AG, and LFB SA, are some of the key players operating in the global platelet-rich plasma market. With the advancement in technology, new players are expected to come in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidences of Sports Injuries
4.2.2 Increasing Number of Androgenic Alopecia Patients
4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas
4.2.4 Rising Prevalence of Arthritis
4.3 Market Restraints
4.3.1 Stringent Regulatory Policies
4.3.2 High Prices of Plasma Therapy
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Pure PRP
5.1.2 Leukocyte-rich PRP
5.1.3 Pure Platelet-rich Fibrin
5.1.4 Leukocyte-rich Fibrin
5.2 By Source
5.2.1 Autologous
5.2.2 Allogenic
5.3 By Application
5.3.1 Orthopedic
5.3.1.1 Arthritis
5.3.1.2 Chronic Tendinitis
5.3.1.3 Bone Repair and Regeneration
5.3.2 Dermatology
5.3.2.1 Androgenic Alopecia
5.3.2.2 Plastic Surgery
5.3.2.3 Cardiac Muscle Injury
5.3.2.4 Dental
5.3.2.5 Nerve Injury
5.3.2.6 Other Applications
5.3.3 By End User
5.3.3.1 Hospitals and Clinics
5.3.3.2 Research Institutes
5.3.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio Product Laboratory Ltd (BPL)
6.1.2 Biolife Plasma Services
6.1.3 Biotest AG
6.1.4 Cambryn Biologics LLC
6.1.5 China Biologic Products Inc.
6.1.6 CSL Ltd
6.1.7 Grifols International SA
6.1.8 Kedrion SpA
6.1.9 LFB SA
6.1.10 Octapharma AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Pure PRP
Leukocyte-rich PRP
Pure Platelet-rich Fibrin
Leukocyte-rich Fibrin
By Source
Autologous
Allogenic
By Application
Orthopedic
Arthritis
Chronic Tendinitis
Bone Repair and Regeneration
Dermatology
Androgenic Alopecia
Plastic Surgery
Cardiac Muscle Injury
Dental
Nerve Injury
Other Applications
By End User
Hospitals and Clinics
Research Institutes
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Pharmacogenomics Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The propelling factors for the growth of the pharmacogenomics market include the increased expenditure in R&D and an increase in the rate of adverse reactions, which has led to the higher adoption of pharmacogenomics in the global market. The increasing focus on precision medicine, along with the need to enhance drug safety and efficacy, is also further fuelling the growth of this market.
The increasing focus on precision medicine is expected to augment the pharmacogenomics market, as the goal of the precision medicine approach is to integrate genetic and environmental information of particular diseases and/or their responses to particular treatments. This is done to determine or assist in targeted drug therapies, as well as in treatment procedures to be adopted to minimize the side effects and improve results, which will require pharmacogenomics extensively. For instance, in the United States, in 2015, the government announced a new precision medicine initiative to accelerate progress toward individualized care that takes genetic variability into account for various chronic disorders.
Pharmacogenomics is also helpful in cancer treatment and has proved to improve the survival of patients, and at the same time, has found to reduce the unnecessary cost due to unresponsive treatment by patients. Hence, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, hence, driving the market growth during the forecast period.
The increasing expenditure in R&D and an increase in the rate of adverse reactions have led to the higher adoption of pharmacogenomics in the global market. Furthermore, there is a rapid increase in the number of research studies related to sequencing, especially next-generation sequencing, which is expected to increase the demand for pharmacogenomic tests in the future.
Scope of the Report
As per the scope of this report, pharmacogenomics is defined as the branch of biotechnology where genomic information is used to study the effect of drugs on an individual, thus, providing accurate insights in making clinical decisions and further determining the most effective way of treatment by varying the dosages of drugs. The field of pharmacogenomics is predicted to treat a wide range of health problems, including cardiovascular diseases, Alzheimer’a disease, cancer, HIV/AIDS, and asthma, in the near future.
Key Market Trends
Drug Discovery is the Segment under Application that is Expected to Grow the Fastest during the Forecast Period
Pharmacogenomics is one of the major emerging trends in the field of medical science, which greatly influences the drug development process. With the use of pharmacogenomics, target identification by drugs has become relatively easy, which ensures much higher chances of success for the approval of drugs. In addition, out of 500 genes, only 50 disease genes have drug availability in the market today. This emphasizes the market opportunity in the future for different manufacturers to concentrate on drug discovery using pharmacogenomics.
Pharmacogenomics has also found applications in the treatment of cancer patients, by anticipating the possible differences in drug response, resistance, efficacy, and toxicity of the chemotherapeutic and targeted immune biologic agents. Therefore, pharmacogenomics for cancer therapy has led to a number of important discoveries in the current cancer treatment, which has helped in the growth of the oncology segment of the market studied.
North America holds the Largest Share of the Market and is Expected to Follow the Same Trend over the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period, due to the presence of high per capita healthcare expenditure, coupled with high patient awareness levels, and the high prevalence of target diseases. Moreover, the increasing preference for personalized treatment, along with its high adoption rate, is further contributing to the growth of the market.
Competitive Landscape
The large interest of researchers and investment in the safety and efficiency of drugs by companies are one the major factors responsible for the growth of the market. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Focus on Precision Medicine
4.2.2 Increasing Expenditure in R&D
4.2.3 High Rate of Adverse Drug Reaction
4.2.4 Enhancement of Drug Safety and Efficiency to Increase Success Rates in Pharmaceutical R&D
4.3 Market Restraints
4.3.1 Difficulties in Detecting Gene Variation that Affect Drug Response
4.3.2 Reimbursement Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 DNA Sequencing
5.1.2 Microarray
5.1.3 Polymerase Chain Reaction
5.1.4 Electrophoresis
5.1.5 Mass Spectrometry
5.1.6 Other Technologies
5.2 By Application
5.2.1 Drug Discovery
5.2.2 Neurology
5.2.3 Oncology
5.2.4 Pain Management
5.2.5 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories Inc.
6.1.2 Biomerieux
6.1.3 AstraZeneca PLC
6.1.4 Bayer AG
6.1.5 Becton, Dickinson and Company
6.1.6 Bio-Rad Laboratories Inc.
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Illumina Inc.
6.1.9 Qiagen
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technology
DNA Sequencing
Microarray
Polymerase Chain Reaction
Electrophoresis
Mass Spectrometry
Other Technologies
By Application
Drug Discovery
Neurology
Oncology
Pain Management
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Personal use Self monitoring Blood Glucose Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 12-06-2019
Market Overview
The personal-use self-monitoring blood glucose (SMBG) market has grown in recent years, due to an increased awareness among diabetes patients. New technological innovations in glucometers and their ease of usage, have made diabetes and pre-diabetes patients more conscientious in monitoring and controlling their blood glucose levels.
Currently, the home user market holds the highest market share and is expected to increase. As a result of this, the demand for home usage of self-monitoring blood glucose devices is not only high among diabetes patients, but also among other people who want to know their health situation regularly.
One of the fastest-growing chronic diseases in the world is diabetes. Diabetes is a disease that occurs when the glucose levels of the body increase to more than the normal level, and the body is unable to produce insulin. Glucometers are used to monitor glucose levels. The type 1 diabetes population around the world is rising, while witnessing a CAGR of 2.13%. As the diabetic population increases, the self-monitoring blood glucose devices market is also bound to increase.
Other factors, such as technological innovations, the convenience of conventional glucose monitoring over regular monitoring, and early detection of hypo- and hyperglycemic diabetes are the primary drivers for market growth.
Scope of the Report
The market is segmented by component (glucometer device, blood glucose test strips, lancets), and geography.
Key Market Trends –
Blood Glucose Test Strips Hold the Highest Market Share
Blood glucose test strips have the highest market share, with 77%, in the global personal usage market of self-monitoring blood glucose (SMBG) devices. As the blood glucose test strips are only for one-time use, the expenditure spent on test strips is high because of the need for their continuous replacement.
The glucometer is considered to be a one-time purchase. Test strips, on the other hand, are supposed to be a continuous investment, as a test strip needs to be disposed of after one use. Thus, this presents a considerable cost impact to the consumers.
Overall, the global demand for blood glucose test strips is projected to witness significant growth over the forecast period. The growth of the market studied is expected to be spurred by the rising global diabetic population.
The growth in market volumes and share of the test strip segment is expected to be better than that of glucometers, because of the difference in use-case frequency. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost, during the same time frame, the corresponding use of multiple (in the range of thousands) test strips may occur, causing a recurrent cost impact.
North America has the Highest Market Share, with a 21.63% CAGR
The North America test strips market has the highest market share, with a revenue of USD 2 billion, followed by Europe and Asia-Pacific.
The United States alone has around 80% share in the North America blood glucose test strips market.
The price policies and favorable reimbursement policies in North America are driving the growth of the North America personal-use glucometer device market.
Competitive Landscape
The global personal-use glucometer market is highly consolidated, with a few major manufacturers having their presence in major regions of the global market, while the remaining manufacturers are limited to other local or region-specific manufacturers.
The innovations in self-monitoring blood glucose devices are increasing and are under development.
ColorSure Dynamic Range Indicator (ColorSure® PLUS) is an expansion of ColorSure® technology from the OneTouch brand. ColorSure PLUS technology is designed to help patients understand when glucose results are nearing highs or lows.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Usage
5.1.1 Personal-use Self-monitoring Blood Glucose Devices (Value and Volume, 2012 – 2024)
5.2 By Component
5.2.1 Glucometer Devices
5.2.2 Test Strips
5.2.3 Lancets
5.3 Geography
5.3.1 North America
5.3.1.1 United States (Value and Volume, 2012 – 2024)
5.3.1.1.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.1.2 Canada (Value and Volume, 2012 – 2024)
5.3.1.2.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.1.3 Rest of North America (Value and Volume, 2012 – 2024)
5.3.1.3.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.2 Europe
5.3.2.1 France (Value and Volume, 2012 – 2024)
5.3.2.1.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.2.2 Germany (Value and Volume, 2012 – 2024)
5.3.2.2.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.2.3 Italy (Value and Volume, 2012 – 2024)
5.3.2.3.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.2.4 Spain (Value and Volume, 2012 – 2024)
5.3.2.4.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.2.5 United Kingdom (Value and Volume, 2012 – 2024)
5.3.2.5.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.2.6 Russia (Value and Volume, 2012 – 2024)
5.3.2.6.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.2.7 Rest of Europe (Value and Volume, 2012 – 2024)
5.3.2.7.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.3 Latin America
5.3.3.1 Mexico (Value and Volume, 2012 – 2024)
5.3.3.1.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.3.2 Brazil (Value and Volume, 2012 – 2024)
5.3.3.2.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.3.3 Rest of Latin America (Value and Volume, 2012 – 2024)
5.3.3.3.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4 Asia-Pacific
5.3.4.1 Japan (Value and Volume, 2012 – 2024)
5.3.4.1.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.2 South Korea (Value and Volume, 2012 – 2024)
5.3.4.2.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.3 China (Value and Volume, 2012 – 2024)
5.3.4.3.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.3.2 By End User (Hospital and Home)
5.3.4.4 India (Value and Volume, 2012 – 2024)
5.3.4.4.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.4.2 By End User (Hospital and Home)
5.3.4.5 Australia (Value and Volume, 2012 – 2024)
5.3.4.5.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.6 Vietnam (Value and Volume, 2012 – 2024)
5.3.4.6.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.7 Malaysia (Value and Volume, 2012 – 2024)
5.3.4.7.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.8 Indonesia (Value and Volume, 2012 – 2024)
5.3.4.8.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.9 Philippines (Value and Volume, 2012 – 2024)
5.3.4.9.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.4.10 Thailand (Value and Volume, 2012 – 2024)
5.3.4.11 Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
5.3.4.11.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.5 Middle East & Africa
5.3.5.1 Saudi Arabia (Value and Volume, 2012 – 2024)
5.3.5.1.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.5.1.2 By End User (Hospital and Home)
5.3.5.2 Iran (Value and Volume, 2012 – 2024)
5.3.5.2.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.5.3 Egypt (Value and Volume, 2012 – 2024)
5.3.5.3.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.5.4 Oman (Value and Volume, 2012 – 2024)
5.3.5.4.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.5.5 South Africa (Value and Volume, 2012 – 2024)
5.3.5.5.1 By Device (Glucometer Device, Test Strips, Lancets)
5.3.5.6 Rest of Middle & Africa (Value and Volume, 2012 – 2024)
5.3.5.6.1 By Device (Glucometer Device, Test Strips, Lancets)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Arkray
7.1.5 Ascensia Diabetes Care
7.1.6 Agamatrix Inc.
7.1.7 Bionime Corporation
7.1.8 Acon
7.1.9 Trivida
7.1.10 Rossmax
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Usage
Personal-use Self-monitoring Blood Glucose Devices (Value and Volume, 2012 – 2024)
By Component
Glucometer Devices
Test Strips
Lancets
Geography
North America
United States (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Canada (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Rest of North America (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Europe
France (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Germany (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Italy (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Spain (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
United Kingdom (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Russia (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Rest of Europe (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Latin America
Mexico (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Brazil (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Rest of Latin America (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Asia-Pacific
Japan (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
South Korea (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
China (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
India (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
Australia (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Vietnam (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Malaysia (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Indonesia (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Philippines (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Thailand (Value and Volume, 2012 – 2024)
Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
Iran (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Egypt (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Oman (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
South Africa (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Rest of Middle & Africa (Value and Volume, 2012 – 2024)
By Device (Glucometer Device, Test Strips, Lancets)
Periodontal Market – Growth, Trends and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 12-06-2019
Market Overview
The growth of the global periodontal market is due to the increasing geriatric population across the world. Medical and dental tourism is experiencing growth in the developing markets, which is also one of the prime factors responsible for the periodontal market growth. Oral hygiene has become one of the most important parameters for staying healthy. This growing awareness about oral hygiene is driving the periodontal market, specifically in the developed countries. However, in developing countries, ignorance of personal hygiene is negatively affecting the growth of the periodontal market.
Reimbursement policies for dental treatments are not adequate in developing countries. There are some policies that provide complete reimbursement for dental procedures, yet people have to pay significantly for such procedures. Inadequate reimbursement plans restrict the growth of the periodontal market. Den-Mat Holdings LLC, Dentsply Sirona, Biohorizons, Dexcel Pharma, and Zimmer Biomet, are some of the major players in the periodontal market.
Scope of the Report
This report estimates the global periodontal market. It includes a detailed analysis of non-surgical as well as surgical methods used in the treatment of periodontal diseases. As per the scope of this report, the periodontal market comprises of the treatment therapies that are currently available for the treatment of periodontal diseases. Local antibiotics, systemic antibiotics, and laser therapy are the widely used non-surgical methods used for the treatment of periodontitis.
Key Market Trends
Surgical Devices Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period
The surgical devices segment is expected to exhibit the fastest growth rate in the overall market over the forecast period. This segment comprises of dental bone implants and dental bone grafts. Dental bone implants hold the largest share in the surgical treatment segment. The dental implants sub-segment is further segmented into endosteal and subperiosteal. Endosteal contributes the largest share in the dental implants sub-segment.
Endosteal (meaning – in the bone) is the most commonly used type of implant. The various types of endosteal include – screws, cylinders, or blades surgically placed into the jawbone. Each implant holds one or more prosthetic teeth. This type of implant is generally used as an alternative, for patients with bridges or removable dentures. The two common types of endosteal implants are – cylinder (also called screw-type) and blade. In both cylinder and blade types, the prosthetic tooth replacement is fabricated to be placed on the abutment portion of the implant. Endosteal implants are also generally more widely available than subperiosteal implants.
However, the obvious disadvantage of endosteal implants is that they require two separate surgical procedures to install, and prolonged healing periods can leave the patient without an implant for a long time. This option is also unsuitable for people with damaged bone tissues in their jaws, which can often result from facial injuries or severe periodontal diseases. Hence, the demand for endosteal implants is expected to increase over the forecast period.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America holds the largest share in the global periodontal market, with the United States being the largest contributor to its revenue. Periodontal disease and tooth decay are the two biggest threats to dental health in the United States. Research studies indicate that gum disease may be linked to several other diseases, including diabetes, heart disease, and certain forms of cancer, and maintaining healthy teeth and gums has become more important than ever. A high burden of periodontal disease in the adult US population is expected, especially among adults aged 65 years and older. Periodontal disease is associated with age, and as US citizens live longer and retain most of their natural teeth, periodontal diseases are expected to gain prominence in the oral health of the adult US population. Therefore, public health programs are required to improve the oral health of US adults.
Competitive Landscape
The global periodontal market is highly competitive and consists of several major players. The existing major players in the periodontal market employ strong competitive strategies, leading to a high rivalry among themselves. Moreover, the increasing level of advertising expense, coupled with powerful strategies, is further increasing the competition among key players. Hence, the presence of major market players, such as Dentsply Sirona, 3M, Medtronic, Straumann, and Zimmer Biomet Inc., is in turn, increasing the overall competitive rivalry in the market. The product advancements and improvement in periodontal products by the major players are increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Aging Population
4.2.2 Growing Medical and Dental Tourism in Developing Markets
4.2.3 Rising Awareness about Oral Health
4.3 Market Restraints
4.3.1 Lack of Proper Reimbursement of Dental Care
4.3.2 Increase in Cost of Periodontal Surgeries
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Therapy
5.1.1 Non-surgical Treatment
5.1.1.1 Local Antibiotics
5.1.1.1.1 Arestin
5.1.1.1.2 Other Local Antibiotics
5.1.1.2 Systemic Antibiotics
5.1.1.2.1 Minocycline
5.1.1.2.2 Doxycycline
5.1.1.2.3 Other Systemic Antibiotics
5.1.1.3 Laser Treatment
5.1.2 Surgical Devices
5.1.2.1 Bone Implants
5.1.2.1.1 Endosteal
5.1.2.1.2 Subperiosteal
5.1.2.2 Bone Grafting
5.1.2.2.1 Allograft
5.1.2.2.2 Xenograft
5.1.2.2.3 Other Bone Grafting
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Den-Mat Holdings LLC
6.1.2 Dentsply Sirona
6.1.3 Dexcel Pharma
6.1.4 3M
6.1.5 Medtronic PLC
6.1.6 Institut Straumann AG
6.1.7 Biohorizons Implant Systems Inc.
6.1.8 Zimmer Biomet Inc.
6.1.9 Danaher Corporation
6.1.10 Valeant Pharmaceuticals International Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Therapy
Non-surgical Treatment
Local Antibiotics
Arestin
Other Local Antibiotics
Systemic Antibiotics
Minocycline
Doxycycline
Other Systemic Antibiotics
Laser Treatment
Surgical Devices
Bone Implants
Endosteal
Subperiosteal
Bone Grafting
Allograft
Xenograft
Other Bone Grafting
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Patient Portal Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 12-06-2019
Market Overview
The increasing growth of the patient portal market has been observed due to the adoption of the patient-centric approach by healthcare payers and increasing demand for electronic health records (EHR) in the market. The current market is also growing as the government is undertaking various initiatives for the patient portals that generally focus on laying down the standards, regulations, and infrastructure for maintaining health records, which may lead to an increase in the demand for patient portal.
The increasing aging population and rise in chronic diseases are putting relentless pressure on the capacity and financial viability of healthcare systems. Healthcare technology, genomics, connected devices, big data analytics, and artificial intelligence are generating vast amounts of health data and insights, which are enabling healthcare providers to make better and faster diagnoses and more informed treatment decisions. These help in transforming the healthcare marketplace from a provider-driven ecosystem to a patient-centric ecosystem. Therefore increasing adoption of the patient-centric approach by healthcare payers and providers is driving the growth of the patient portal market.
The growth of the patient portal market is also due to the increasing geriatric population and the increasing incidence of osteoarthritis disease. The increasing prevalence of osteoarthritis and the introduction of innovative technologies for the treatment of osteoarthritis are found to be the primary factors that are expected to be responsible for the growth of the patient portal market during the forecast period.
The market is also experiencing growth as a result of the increase in demand for EHR (electronic health records), as they have become increasingly more important for patients and providers. EHR systems are becoming increasingly popular as the healthcare industry is moving toward digitization. There are several government initiatives that generally focus on laying down the standards, regulations, and infrastructure for maintaining health records, which may lead to an increase in the demand for patient portals.
Scope of the Report
As per the scope of the report, the patient portal is a web-based access point that is connected with the electronic health records (EHR) systems and is focused on the patient’s access to health records. The patients can share their health information and communicate remotely. These allow patients to look into various data points. Some portals allow patients to check medical history data and view demographics.
Key Market Trends
Integrated Patient Portal Holds the Largest Share in the Portal Segment
The integrated patient portal is more preferred because of the electronic health record (EHR) and holds a significant share in the patient portal market. This portal is likely to dominate the market as it provides more feature for patients, ease of use and allows the patient to access the complete record/history at one place from anywhere and anytime. Currently, the integrated patient portal is commonly used service in the US and expected same way across the globe, and the market to grow positively.
North America was Observed to be the Largest Patient Portal Market
North America has been the largest patient portal market due to wide technological advancements in the region. Countries, such as the United States and Canada, have been successful in implementing IT technologies in their healthcare systems, which as a result, may boost the market growth. Moreover, the presence of developed IT and healthcare infrastructure, promising government initiatives to give patients access to their healthcare data at any time anywhere via the patient portal and in the current healthcare infrastructure, and constantly improving reimbursement scenario are expected to further propel the market growth.
Competitive Landscape
Over the past decade, an opportunity has been presented for pharmaceutical companies to dominate the digital patient engagement arena. The pharmaceutical and medical device companies are also moving toward data-driven models and leveraging IT for business model transformation.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Adoption of Patient-centric Approach by Healthcare Payers
4.2.2 Increase in the Demand for Electronic Health Records (EHRs)
4.2.3 Rising Popularity of Patient Portals Among Geriatric Population
4.2.4 Favorable Government Funding Policies and Initiatives for Implementing Healthcare IT Solutions
4.3 Market Restraints
4.3.1 Data Privacy and Security Concerns
4.3.2 High Cost of Implementation and Deployment
4.3.3 Requirement of Infrastructural Investments to Support Patient Portals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Portal
5.1.1 Integrated Patient Portal
5.1.2 Standalone Patient Portal
5.2 By Delivery Mode
5.2.1 Web-based Delivery
5.2.2 Cloud-based Delivery
5.3 By End User
5.3.1 Provider
5.3.2 Payer
5.3.3 Pharmacy
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions Inc.
6.1.2 Mckesson Corporation
6.1.3 Curemd Healthcare
6.1.4 Athenahealth Inc.
6.1.5 Cerner Corporation
6.1.6 Nextgen Healthcare Information Systems LLC
6.1.7 GE Healthcare
6.1.8 Greenway Health LLC
6.1.9 Medfusion Inc.
6.1.10 Eclinicalworks LLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Portal
Integrated Patient Portal
Standalone Patient Portal
By Delivery Mode
Web-based Delivery
Cloud-based Delivery
By End User
Provider
Payer
Pharmacy
Other End Users
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America